Login to Your Account



Prosensa, GSK Ink Potential $678M Antisense DMD Pact

By Cormac Sheridan


Wednesday, October 14, 2009
Prosensa Therapeutics BV is banking an up-front payment of £16 million (US$25.3 million) and could earn up to £412 million more from an RNA-based drug development alliance with GlaxoSmithKline plc in the X-linked neuromuscular disorder Duchenne's muscular dystrophy (DMD). (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription